image

Report Scope & Overview:

The Multiple Sclerosis (MS) Market size was valued at USD 23.2 billion in 2022 and is expected to reach USD 28.21 billion by 2030 and grow at a CAGR of 2.2% over the forecast period of 2023-2030.

Multiple sclerosis disease is a neurological disorder in which the immune system attacks the myelin, Myelin is a layer that forms around the nerves, myelin is made up of protein and fatty acids, Myelin protects the nerves of the central nervous system and peripheral nervous system, sclerosis term is generally defined when the nerves or the myelin gets attacked the tissue gets affected or gets shredded and scars are formed this scars are denoted sclerosis, there are four types of MS (CIS) clinically isolated syndrome (RRMS) relapsing-remitting MS (PPMS) primary progressive SPMS Secondary progressive, patients suffering from multiple sclerosis faced mild symptoms during the early stages which include muscle weakness, fatigue loss of coordination’s and when the diseases gets intensifying the patients is likely to face difficulty in walking, memory-related issues and many other symptoms which will be explained in final report. The rising awareness of the disease all around the globe is contributing to the growth of the multiple sclerosis market. The rise in the number of multiple sclerosis patients all around the globe to be precise patients in European countries and American countries increases the demand for the multiple sclerosis market, according to our analysis a lot of initiatives is been taken by private health institutions and governments in order to prevent the multiple sclerosis disease in the early stages and new drugs, injections and medicines are been introduced globally in order to make sure people suffering from multiple sclerosis gets proper quality treatment. 

Multiple Sclerosis (MS) Market Revenue Analysis

To Get More Information on Multiple Sclerosis Market - Request Free Sample Report

Impact of Covid-19

The healthcare industry had to face a lot of problems related to providing services and access to patients suffering from multiple sclerosis. The lockdown rules imposed by the government all around the globe made it difficult for patients to visit the clinics and have access to doctors, covid-19 disrupted the supply chain management of key players which impacted the revenue factor as the supply of drugs could not match up the demand of patients. Though the hospitals were operating still there was a fear among the MS patients regarding the covid-19 as the regular visit to hospitals and clinics may be the reason why the MS patients might get COVID-19.

Market Dynamics

Drivers

  • Rise in the awareness all around the globe regarding the MS.

  • Rise in the innovations related to drugs, and treatment of multiple sclerosis.   

Restrain

  • Expensive treatment, as the cost of the treatments are very high and it might create problems for patients of emerging or underdeveloped regions. 

Opportunity

  • Increase in the technological advancement in the healthcare industry.

  • Increase in the initiatives taken by the government and healthcare org to create awareness about the disease and provide good quality treatment to patients.

Challenge

  • Lack of skillful healthcare professionals.

Impact of ongoing recession:

Recession may have a moderate effect on the global multiple sclerosis market as we mentioned earlier the price of the disease treatment is high, it will all be dependent on the perspective of the patients chances are people might ignore the symptoms during the early stage of the disease, the previous recession 2009 clearly dictated the fact that the number of patients visiting the hospitals declined during the recession as recession brings economic disturbance on a personal level and on a global level, This report will give a brief about how the recession will impact the multiple sclerosis market in the developed countries all around the globe because recession will not bring a common situation every other nation will face different crisis because of recession which might.

Key Market Segmentation

By Drug Class

  • Disease Modifying Drugs (DMDs)

  • Beta Interferons

  • Immunosuppressants

  • Synthetic Immunomodulatory Drugs

  • Chemotherapy Drugs

  • Corticosteroids

  • Others

By Disease Type

  • Relapsing-remitting MS (RRMS)

  • Secondary Progressive MS (SPMS)

  • Primary Progressive MS (PPMS)

  • Progressive Relapsing MS (PRMS)

By Mode of Administration

  • Oral

  • Injectable

By Distribution Channel

Multiple Sclerosis (MS) Market Segmentation Analysis

Need any customization research on Multiple Sclerosis Market - Enquiry Now

Regional Analysis

North America is expected to witness the highest growth and will continue to do during the forecasted period, the rise in the number of research and developments related to multiple sclerosis and new launch of products which is beneficial during the treatment of the disease in this region is the major reason because of which there is an immense growth in North America and the continuous initiatives taken by the government to create awareness in that region is the major element because of which multiple sclerosis market will be growing at a good pace in North America.

Europe will also show good growth as the demand for multiple sclerosis increases and the rising initiative taken by the government to make sure that the patients suffering from the disease in those regions get proper treatment.

APAC will also share good growth due to the rising awareness about the disease and the government initiatives to increase technological advancement in order to provide better treatment to patients.

REGIONAL COVERAGE:

  • North America

    • USA

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • The Netherlands

    • Rest of Europe

  • Asia-Pacific

    • Japan

    • south Korea

    • China

    • India

    • Australia

    • Rest of Asia-Pacific

  • The Middle East & Africa

    • Israel

    • UAE

    • South Africa

    • Rest of Middle East & Africa

  • Latin America

    • Brazil

    • Argentina

    • Rest of Latin America

Key Players

The major key players Johnson & Johnson, Biogen, Teva Neuroscience, Inc., Genentech, Inc., Dr. Reddy's, Zydus Cadila, Berlex, Sanofi, Novartis AG, Merck KGaA, and Other Players.

Berlex-Company Financial Analysis

​​​​​​​

Recent developments

  • Biogen “The initiative taken by the company to innovate and be the pioneers in terms of disruptive therapies of MS prevention and the increase R&D to provide and improve the best outcomes,

  • Teva Neuroscience, Inc.; The continuous effort taken by the company to develop new treatments and drugs to provide treatment that covers conditions like migraine, movement disorder, and neurodegenerative disorder also the company organizes campaigns and programs for patients all around the globe so that patient can discuss and interact with people are experiencing the similar symptoms also, they help the patients to boost their confidence which is very essential.

Multiple Sclerosis Market Report Scope:
Report Attributes Details
Market Size in 2022  US$ 23.2 Bn
Market Size by 2030  US$ 28.21 Bn
CAGR   CAGR of 2.2% From 2023 to 2030
Base Year  2022
Forecast Period  2023-2030
Historical Data  2019-2021
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Drug Class (Disease Modifying Drugs (DMDs), Beta Interferons, Immunosuppressants, Synthetic Immunomodulatory Drugs, Chemotherapy Drugs, Corticosteroids, Others)
• By disease Type (Relapsing-remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), Progressive Relapsing MS (PRMS))
• By Mode of administration (Oral, Injectable)
• By Distribution Channel (Hospital Based Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Johnson & Johnson, Biogen, Teva Neuroscience, Inc., Genentech, Inc., Dr. Reddy's, Zydus Cadila, Berlex, Sanofi, Novartis AG, Merck KGaA, Others
Key Drivers • Rise in the awareness all around the globe regarding the MS.
• Rise in the innovations related to drugs, treatment of multiple sclerosis.
Market Opportunities • Lack of skill-full healthcare professionals.

 

Frequently Asked Questions

Ans: The Multiple Sclerosis (MS) Market size was valued at USD 23.2 Bn in 2022.

Ans: The Multiple Sclerosis [MS] Market is to growing at a CAGR of 2.2% Over the Forecast Period 2023-2030.

The major key players Johnson & Johnson, Biogen, Teva Neuroscience, Inc., Genentech, Inc., Dr. Reddy's, Zydus Cadila, Berlex, Sanofi, Novartis AG, Merck KGaA, Others

Recession may have a moderate effect on the global multiple sclerosis market as we mentioned earlier the price of the disease treatment is high

North America is expected to witnessing the highest growth and will continue to do during the forecasted period

Table of Contents

1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions

2. Research Methodology

3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges

4. Impact Analysis
4.1 COVID 19 Impact Analysis
4.2 Impact of ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World

5. Value Chain Analysis

6. Porter’s 5 forces model

7. PEST Analysis

8. Global Multiple Sclerosis (MS) Market Segmentation By Drug Class
8.1 Disease Modifying Drugs (DMDs)
8.2 Beta Interferons
8.3 Immunosuppressants
8.4 Synthetic Immunomodulatory Drugs
8.5 Chemotherapy Drugs
8.6 Corticosteroids
8.7 Others

9. Global Multiple Sclerosis (MS) Market Segmentation By Disease Type
9.1 Relapsing-remitting MS (RRMS)
9.2 Secondary Progressive MS (SPMS)
9.3 Primary Progressive MS (PPMS)
9.4 Progressive Relapsing MS (PRMS)

10. Global Multiple Sclerosis (MS) Market Segmentation By Mode of Administration
10.1 Oral
10.2 Injectable

11. Global Multiple Sclerosis (MS) Market Segmentation By Distribution Channel
11.1 Hospital Based Pharmacy
11.2 Retail Pharmacy
11.3 Online Pharmacy
11.4 Others

12. Regional Analysis
12.1 Introduction
12.2 North America
12.2.1 North America Global Multiple Sclerosis (MS) Market by country
12.2.2North America Global Multiple Sclerosis (MS) Market by Drug Class
12.2.3 North America Global Multiple Sclerosis (MS) Market by Disease Type
12.2.4 North America Global Multiple Sclerosis (MS) Market by Mode of Administration
12.2.5 North America Global Multiple Sclerosis (MS) Market by Distribution Channel
12.2.6 USA
12.2.6.1 USA Global Multiple Sclerosis (MS) Market by Drug Class
12.2.6.2 USA Global Multiple Sclerosis (MS) Market by Disease Type
12.2.6.3 USA Global Multiple Sclerosis (MS) Market by Mode of Administration
12.2.6.4 USA Global Multiple Sclerosis (MS) Market by Distribution Channel
12.2.7 Canada
12.2.7.1 Canada Global Multiple Sclerosis (MS) Market by Drug Class
12.2.7.2 Canada Global Multiple Sclerosis (MS) Market by Disease Type
12.2.7.3 Canada Global Multiple Sclerosis (MS) Market by Mode of Administration
12.2.7.4 Canada Global Multiple Sclerosis (MS) Market by Distribution Channel
12.2.8 Mexico
12.2.8.1 Mexico Global Multiple Sclerosis (MS) Market by Drug Class
12.2.8.2 Mexico Global Multiple Sclerosis (MS) Market by Disease Type
12.2.8.3 Mexico Global Multiple Sclerosis (MS) Market by Mode of Administration
12.2.8.4 Mexico Global Multiple Sclerosis (MS) Market by Distribution Channel
12.3 Europe
12.3.1 Europe Global Multiple Sclerosis (MS) Market by country
1.3.3.2 Europe Global Multiple Sclerosis (MS) Market by Drug Class
12.3.3 Europe Global Multiple Sclerosis (MS) Market by Disease Type
12.3.4 Europe Global Multiple Sclerosis (MS) Market by Mode of Administration
12.3.5 Europe Global Multiple Sclerosis (MS) Market by Distribution Channel
12.3.6 Germany
12.3.6.1 Germany Global Multiple Sclerosis (MS) Market by Drug Class
12.3.6.2 Germany Global Multiple Sclerosis (MS) Market by Disease Type
12.3.6.3 Germany Global Multiple Sclerosis (MS) Market by Mode of Administration
12.3.6.4 Germany Global Multiple Sclerosis (MS) Market by Distribution Channel
12.3.7 UK
12.3.7.1 UK Global Multiple Sclerosis (MS) Market by Drug Class
12.3.7.2 UK Global Multiple Sclerosis (MS) Market by Disease Type
12.3.7.3 UK Global Multiple Sclerosis (MS) Market by Mode of Administration
12.3.7.4 UK Global Multiple Sclerosis (MS) Market by Distribution Channel
12.3.8 France
12.3.8.1 France Global Multiple Sclerosis (MS) Market by Drug Class
12.3.8.2 France Global Multiple Sclerosis (MS) Market by Disease Type
12.3.8.3 France Global Multiple Sclerosis (MS) Market by Mode of Administration
12.3.8.4 France Global Multiple Sclerosis (MS) Market by Distribution Channel
12.3.9 Italy
12.3.9.1 Italy Global Multiple Sclerosis (MS) Market by Drug Class
12.3.9.2 Italy Global Multiple Sclerosis (MS) Market by Disease Type
12.3.9.3 Italy Global Multiple Sclerosis (MS) Market by Mode of Administration
12.3.9.4 Italy Global Multiple Sclerosis (MS) Market by Distribution Channel
12.3.10 Spain
12.3.10.1 Spain Global Multiple Sclerosis (MS) Market by Drug Class
12.3.10.2 Spain Global Multiple Sclerosis (MS) Market by Disease Type
12.3.10.3 Spain Global Multiple Sclerosis (MS) Market by Mode of Administration
12.3.10.4 Spain Global Multiple Sclerosis (MS) Market by Distribution Channel
12.3.11 The Netherlands
12.3.11.1 Netherlands Global Multiple Sclerosis (MS) Market by Drug Class
12.3.11.2 Netherlands Global Multiple Sclerosis (MS) Market by Disease Type
12.3.11.3 Netherlands Global Multiple Sclerosis (MS) Market by Mode of Administration
12.3.11.4 Netherlands Global Multiple Sclerosis (MS) Market by Distribution Channel
12.3.12 Rest of Europe
12.3.12.1 Rest of Europe Global Multiple Sclerosis (MS) Market by Drug Class
12.3.12.2 Rest of Europe Global Multiple Sclerosis (MS) Market by Disease Type
12.3.12.3 Rest of Europe Global Multiple Sclerosis (MS) Market by Mode of Administration
12.3.12.4 Rest of Europe Global Multiple Sclerosis (MS) Market by Distribution Channel
12.4 Asia-Pacific
12.4.1 Asia Pacific Global Multiple Sclerosis (MS) Market by country
12.4.2 Asia Pacific Global Multiple Sclerosis (MS) Market by Drug Class
12.4.3 Asia Pacific Global Multiple Sclerosis (MS) Market by Disease Type
12.4.4Asia Pacific Global Multiple Sclerosis (MS) Market by Mode of Administration
12.4.5Asia Pacific Global Multiple Sclerosis (MS) Market by Distribution Channel
12.4.6 Japan
12.4.6.1 Japan Global Multiple Sclerosis (MS) Market by Drug Class
12.4.6.2 Japan Global Multiple Sclerosis (MS) Market by Disease Type
12.4.6.3 Japan Global Multiple Sclerosis (MS) Market by Mode of Administration
12.4.6.4 Japan Global Multiple Sclerosis (MS) Market by Distribution Channel
12.4.7 South Korea
12.4.7.1 South Korea Global Multiple Sclerosis (MS) Market by Drug Class
12.4.7.2 South Korea Global Multiple Sclerosis (MS) Market by Disease Type
12.4.7.3 South Korea Global Multiple Sclerosis (MS) Market by Mode of Administration
12.4.7.4 South Korea Global Multiple Sclerosis (MS) Market by Distribution Channel
12.4.8 China
12.4.8.1 China Global Multiple Sclerosis (MS) Market by Drug Class
12.4.8.2 China Global Multiple Sclerosis (MS) Market by Disease Type
12.4.8.3 China Global Multiple Sclerosis (MS) Market by Mode of Administration
12.4.8.4 China Global Multiple Sclerosis (MS) Market by Distribution Channel
12.4.9 India
12.4.9.1 India Global Multiple Sclerosis (MS) Market by Drug Class
12.4.9.2 India Global Multiple Sclerosis (MS) Market by Disease Type
12.4.9.3 India Global Multiple Sclerosis (MS) Market by Mode of Administration
12.4.9.4 India Global Multiple Sclerosis (MS) Market by Distribution Channel
12.4.10 Australia
12.4.10.1 Australia Global Multiple Sclerosis (MS) Market by Drug Class
12.4.10.2 Australia Global Multiple Sclerosis (MS) Market by Disease Type
12.4.10.3 Australia Global Multiple Sclerosis (MS) Market by Mode of Administration
12.4.10.4 Australia Global Multiple Sclerosis (MS) Market by Distribution Channel
12.4.11 Rest of Asia-Pacific
12.4.11.1 APAC Global Multiple Sclerosis (MS) Market by Drug Class
12.4.11.2 APAC Global Multiple Sclerosis (MS) Market by Disease Type
12.4.11.3 APAC Global Multiple Sclerosis (MS) Market by Mode of Administration
12.4.11.4 APAC Global Multiple Sclerosis (MS) Market by Distribution Channel
12.5 The Middle East & Africa
12.5.1 The Middle East & Africa Global Multiple Sclerosis (MS) Market by country
12.5.2 The Middle East & Africa Global Multiple Sclerosis (MS) Market by Drug Class
12.5.3 The Middle East & Africa Global Multiple Sclerosis (MS) Market by Disease Type
12.5.4The Middle East & Africa Global Multiple Sclerosis (MS) Market by Mode of Administration
12.5.5 The Middle East & Africa Global Multiple Sclerosis (MS) Market by Distribution Channel
12.5.6 Israel
12.5.6.1 Israel Global Multiple Sclerosis (MS) Market by Drug Class
12.5.6.2 Israel Global Multiple Sclerosis (MS) Market by Disease Type
12.5.6.3 Israel Global Multiple Sclerosis (MS) Market by Mode of Administration
12.5.6.4 Israel Global Multiple Sclerosis (MS) Market by Distribution Channel
12.5.7 UAE
12.5.7.1 UAE Global Multiple Sclerosis (MS) Market by Drug Class
12.5.7.2 UAE Global Multiple Sclerosis (MS) Market by Disease Type
12.5.7.3 UAE Global Multiple Sclerosis (MS) Market by Mode of Administration
12.5.7.4 UAE Global Multiple Sclerosis (MS) Market by Distribution Channel
12.5.8 South Africa
12.5.8.1 South Africa Global Multiple Sclerosis (MS) Market by Drug Class
12.5.8.2 South Africa Global Multiple Sclerosis (MS) Market by Disease Type
12.5.8.3 South Africa Global Multiple Sclerosis (MS) Market by Mode of Administration
12.5.8.4 South Africa Global Multiple Sclerosis (MS) Market by Distribution Channel
12.5.9 Rest of Middle East & Africa
12.5.9.1 Rest of Middle East & Asia Global Multiple Sclerosis (MS) Market by Drug Class
12.5.9.2 Rest of Middle East & Asia Global Multiple Sclerosis (MS) Market by Disease Type
12.5.9.3 Rest of Middle East & Asia Global Multiple Sclerosis (MS) Market Mode of Administration
12.5.9.4 Rest of Middle East & Asia Global Multiple Sclerosis (MS) Market by Distribution Channel
12.6 Latin America
12.6.1 Latin America Global Multiple Sclerosis (MS) Market by country
12.6.2 Latin America Global Multiple Sclerosis (MS) Market by Drug Class
12.6.3 Latin America Global Multiple Sclerosis (MS) Market by Disease Type
12.6.4 Latin America Global Multiple Sclerosis (MS) Market by Mode of Administration
12.6.5  Latin America Global Multiple Sclerosis (MS) Market by Distribution Channel
12.6.6 Brazil
12.6.6.1 Brazil Global Multiple Sclerosis (MS) Market by Drug Class
12.6.6.2 Brazil Africa Global Multiple Sclerosis (MS) Market by Disease Type
12.6.6.3Brazil Global Multiple Sclerosis (MS) Market by Mode of Administration
12.6.6.4 Brazil Global Multiple Sclerosis (MS) Market by Distribution Channel
12.6.7 Argentina
12.6.7.1 Argentina Global Multiple Sclerosis (MS) Market by Drug Class
12.6.7.2 Argentina Global Multiple Sclerosis (MS) Market by Disease Type
12.6.7.3 Argentina Global Multiple Sclerosis (MS) Market by Mode of Administration
12.6.7.4 Argentina Global Multiple Sclerosis (MS) Market by Distribution Channel
12.6.8 Rest of Latin America
12.6.8.1 Rest of Latin America Global Multiple Sclerosis (MS) Market by Drug Class
12.6.8.2 Rest of Latin America Global Multiple Sclerosis (MS) Market by Disease Type
12.6.8.3 Rest of Latin America Global Multiple Sclerosis (MS) Market by Mode of Administration
12.6.8.4 Rest of Latin America Global Multiple Sclerosis (MS) Market by Distribution Channel

13. Company Profile
13.1 Johnson & Johnson
13.1.1 Market Overview
13.1.2 Financials
13.1.3 Product/Services/Offerings
13.1.4 SWOT Analysis
13.1.5 The SNS View
13.2 Biogen
13.2.1 Market Overview
13.2.2 Financials
13.2.3 Product/Services/Offerings
13.2.4 SWOT Analysis
13.2.5 The SNS View
13.3 Teva Neuroscience, Inc
13.3.1 Market Overview
13.3.2 Financials
13.3.3 Product/Services/Offerings
13.3.4 SWOT Analysis
13.3.5 The SNS View
13.4 Genentech, Inc
13.4.1 Market Overview
13.4.2 Financials
13.4.3 Product/Services/Offerings
13.4.4 SWOT Analysis
13.4.5 The SNS View
13.5 , Dr. Reddy’s
13.5.1 Market Overview
13.5.2 Financials
13.5.3 Product/Services/Offerings
13.5.4 SWOT Analysis
13.5.5 The SNS View
13.6 Zydus Cadila
13.6.1 Market Overview
13.6.2 Financials
13.6.3 Product/Services/Offerings
13.6.4 SWOT Analysis
13.6.5 The SNS View
13.7 Berlex
13.7.1 Market Overview
13.7.2 Financials
13.7.3 Product/Services/Offerings
13.7.4 SWOT Analysis
13.7.5 The SNS View
13.8 Sanofi
13.8.1 Market Overview
13.8.2 Financials
13.8.3 Product/Services/Offerings
13.8.4 SWOT Analysis
13.8.5 The SNS View
13.9 Novartis AG
13.9.1 Market Overview
13.9.2 Financials
13.9.3 Product/Services/Offerings
13.9.4 SWOT Analysis
13.9.5 The SNS View
13.10 Merck KGaA
13.10.1 Market Overview
13.10.2 Financials
13.10.3 Product/Services/Offerings
13.10.4 SWOT Analysis
13.10.5 The SNS View
13. Others 
13.10.1 Market Overview
13.10.2 Financials
13.10.3 Product/Services/Offerings
13.10.4 SWOT Analysis
13.10.5 The SNS View

14. Competitive Landscape
14.1 Competitive Benchmarking
14.2 Market Share Analysis
14.3 Recent Developments

15. Used Cases and Best Practices

16. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone